Attached files

file filename
EX-10.1 - EXHIBIT 10.1 - Semler Scientific, Inc.t1401398_ex10-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

 

 

FORM 8-K

  

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2014

  

 

 

SEMLER SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36305 26-1367393
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

2330 NW Everett St.

Portland, Oregon

97210
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (877) 774-4211

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Effective as of July 24, 2014, Semler Scientific, Inc. (the “Company”), entered into an indemnification agreement in the form approved by the board of directors of the Company (the “Board”) on July 24, 2014, with each current director and executive officer of the Company.

 

Under each indemnification agreement, the Company agreed, among other things, to indemnify each director and executive officer, under the circumstances and to the extent provided for therein, to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding arising out of the person’s services as a director or executive officer. The indemnification agreement also provides for the advancement of expenses relating to the indemnification obligations.

 

The foregoing summary of the terms of the indemnification agreement is qualified in its entirety by reference to, and should be read in conjunction with, the complete text of the form of the indemnification agreement. The form of indemnification agreement is filed as Exhibit 10.1 to this report and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d)        Exhibits

 

Exhibit No.   Description
10.1   Form of Indemnification Agreement, approved and entered into between the Company and each of the Company’s directors and executive officers as of July 24, 2014.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  SEMLER SCIENTIFIC, INC.
   
  By: /s/ Dan Conger

  Name: Dan Conger
  Title: VP Finance

 

Date: July 29, 2014